Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Amira Pharmaceuticals

Request full access

Small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat

San Diego, United StatesFounded 2005Biotech & Life Sciences

About Amira Pharmaceuticals

Amira Pharmaceuticals, established in 2005 in San Diego, CA, operated as a small-molecule pharmaceutical company concentrating on the discovery and initial development of novel drugs for inflammatory and fibrotic diseases. The scientific founding team, which included Peppi Prasit, Jilly Evans, and John Hutchinson, were veterans of Merck. Their collective experience was instrumental in the discovery of multiple drugs, including the well-known anti-inflammatory medication Singulair®. This team of seasoned 'drug hunters' formed Amira with minimal initial intellectual property, aiming to replicate their past successes by identifying new disease pathways and developing high-value compounds.

The company's business model focused on combining the rigorous, effective decision-making of a large pharmaceutical firm with the agile and energetic environment of a small startup. This approach enabled the efficient development of novel compounds. Amira's primary activities involved preclinical and early-phase clinical research into bioactive lipid pathways and complex signaling processes that control conditions like asthma, cardiovascular disease, and fibrosis. A key partnership was established with GlaxoSmithKline to co-develop FLAP (5-lipoxygenase activating protein) inhibitors for respiratory and cardiovascular diseases.

A significant milestone for Amira was the development of its fibrosis program, headlined by the lead asset AM152. This orally available LPA1 receptor antagonist was developed for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (scleroderma). By 2011, AM152 had successfully completed Phase I clinical trials and was prepared for Phase IIa studies. The company also developed a preclinical autotaxin program with potential applications in treating neuropathic pain and cancer metastases. In September 2011, Amira Pharmaceuticals was acquired by Bristol-Myers Squibb, becoming a wholly-owned subsidiary. The transaction involved an upfront cash payment of $325 million, with an additional $150 million in potential milestone payments, marking a significant validation of Amira's drug discovery platform and pipeline.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2005
Headquarters
San Diego, United States
Employees
17
Open positions
None listed
Dealroom signal
41.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jul 2011 $475M $475M Bristol-Myers Squibb —
SERIES B✓Equity / VC Mar 2007 $25M $100M Prospect Venture Partners · Novo Holdings · Versant Ventures · Avalon Ventures —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Amira Pharmaceuticals website traffic

Latest recorded traffic for Amira Pharmaceuticals is 90 monthly website visits. Amira Pharmaceuticals's team grew 6.3% over the past year.

Latest monthly visits90 1-year team growth+6.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Amira Pharmaceuticals in the San Diego ecosystem

Live from Dealroom

The Amira Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Avalon Ventures
  • Prospect Venture Partners
  • Versant Ventures
  • Novo Seeds
  • Novo Holdings

Other known investors1 additional known investor

  • Bristol-Myers Squibb
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States50%
🇧🇦 Bosnia and Herzegovina25%
🏳️ Sudan25%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Amira Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amira Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.